Table 1

Sociodemographic and clinical characteristics of patients receiving voriconazole TDM between 2007-2009
Variable Patients with voriconazole drug monitoring [n, (%)]
Number of patients 108
Median Age (IQR) 53 (38–64)
Sex, % male 59 (54.6%)
Underlying condition
Hematopoietic stem cell transplant 47 (43.5%)
Hematologic malignancy without a stem cell transplant 37 (34.3%)
Solid organ transplantation 10 (9.3%)
Other condition 9 (8.3%)
None 3 (2.8%)
Reason for voriconazole treatment*
Invasive pulmonary aspergillosis 83 (76.8%)
Invasive sinus or CNS aspergillosis 5 (4.6%)
Invasive candidal infection 9 (8.3%)
Other invasive fungal infectionδ 13 (12.0%)
Febrile neutropenia 9 (8.3%)
Diagnosis of infection
Proven or probable invasive fungal disease 46 (42.5%)
Possible invasive fungal disease 43 (39.8%)
Voriconazole initial drug level
Subtherapeutic (<1.0 mg/L) 32 (29.6%)
Therapeutic (1.0-5.5 mg/L) 64 (59.2%)
Supratherapeutic (>5.5 mg/L) 12 (11.1%)

*Sixteen patients received voriconazole therapy for more than one indication.

δ Other fungal organisms included Fusarium (n = 2), Absidia (n = 1), Alternaria (n = 1), Saccharomyces (n = 1), Scedosporium (n = 1), Ascomyctes (n = 1), Rhizopus (n = 1), Pseudoallescheria (n = 1), and Paecilomyces (n = 1).

Chu et al.

Chu et al. BMC Infectious Diseases 2013 13:105   doi:10.1186/1471-2334-13-105

Open Data